VeriMom¿Es sr-(tetrapeptide-74 hexapeptide-40 expression vector pmbp-parallel 1 polypeptide-1 spider polypeptide-1 spider polypeptide-5) seguro durante el embarazo?
No harmonised CLP classification, SCCS or CIR reproductive safety assessments, or peer‑reviewed reproductive/toxicity studies identified for the named peptides. These are peptide/protein actives (high molecular weight, proteolytically degradable) with expected minimal dermal systemic bioavailability when used topically, and no evidence of teratogenicity or endocrine activity was found in available sources (ECHA Annex VI; PubMed; CosIng; PubChem).
Related ingredients
Frequently asked questions
- ¿Es sr-(tetrapeptide-74 hexapeptide-40 expression vector pmbp-parallel 1 polypeptide-1 spider polypeptide-1 spider polypeptide-5) seguro durante el embarazo?
- No harmonised CLP classification, SCCS or CIR reproductive safety assessments, or peer‑reviewed reproductive/toxicity studies identified for the named peptides. These are peptide/protein actives (high molecular weight, proteolytically degradable) with expected minimal dermal systemic bioavailability when used topically, and no evidence of teratogenicity or endocrine activity was found in available sources (ECHA Annex VI; PubMed; CosIng; PubChem).
- ¿Es sr-(tetrapeptide-74 hexapeptide-40 expression vector pmbp-parallel 1 polypeptide-1 spider polypeptide-1 spider polypeptide-5) seguro durante la lactancia?
- No data indicating reproductive or lactation hazard, no harmonised classifications, and no mechanistic evidence for transfer into breast milk. Topically applied peptides are expected to be degraded and have negligible systemic exposure; no studies suggest transfer to breast milk or effects on nursing infants (sources searched: ECHA Annex VI, PubMed, CosIng, PubChem).
- ¿Es sr-(tetrapeptide-74 hexapeptide-40 expression vector pmbp-parallel 1 polypeptide-1 spider polypeptide-1 spider polypeptide-5) seguro para la piel del bebé?
- No toxicity or developmental data specific to infants found. Adult hazard/mechanism assessments are absent. Although dermal absorption of intact peptides is expected to be very low, infant (0–3 yr) skin has higher surface-area-to-weight and immature barrier function, so exposure score is increased by +1 to reflect potentially higher but still likely low absorption; no evidence of infant-specific adverse effects was identified (sources: PubMed, CosIng, ECHA Annex VI, PubChem).
- ¿Cómo puntúa VeriMom a sr-(tetrapeptide-74 hexapeptide-40 expression vector pmbp-parallel 1 polypeptide-1 spider polypeptide-1 spider polypeptide-5)?
- VeriMom puntúa sr-(tetrapeptide-74 hexapeptide-40 expression vector pmbp-parallel 1 polypeptide-1 spider polypeptide-1 spider polypeptide-5) en 100/100 (sin riesgos conocidos) según el estado EU CosIng, clasificaciones ECHA y estudios PubMed.
- ¿Cuáles son las alternativas seguras a sr-(tetrapeptide-74 hexapeptide-40 expression vector pmbp-parallel 1 polypeptide-1 spider polypeptide-1 spider polypeptide-5) en el embarazo?
- Consulta nuestra lista de alternativas seguras a sr-(tetrapeptide-74 hexapeptide-40 expression vector pmbp-parallel 1 polypeptide-1 spider polypeptide-1 spider polypeptide-5) según función similar y clasificación sin riesgos conocidos.
Comprueba cualquier etiqueta en 2 segundos
Descarga VeriMom gratis — escanea cualquier producto y ve la puntuación de seguridad en el embarazo al instante.
Aviso Médico
Esta información es solo para fines educativos y no constituye asesoramiento médico. Las puntuaciones de seguridad se basan en datos disponibles públicamente y pueden no reflejar todos los riesgos. Siempre consulte a su profesional de salud antes de usar cualquier producto durante el embarazo o la lactancia.